Clinical Trial: Bevacizumab Intravitreal for Myopic Choroidal Neovascularization

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Bevacizumab Intravitreal for Myopic Choroidal Neovascularization

Brief Summary: To evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).

Detailed Summary: Nineteen consecutive patients (19 eyes) with subfoveal PM-CNV, 18 of whom had been unsuccessfully treated with Visudyne PDT, were treated with IVT of 1.25 mg bevacizumab or 0.5mg ranibizumab. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. IVTs were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 6 months.
Sponsor: Instituto de Olhos de Goiania

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Instituto de Olhos de Goiania

Dates:
Date Received: November 24, 2008
Date Started: January 2007
Date Completion:
Last Updated: November 24, 2008
Last Verified: November 2008